BROMODEOXYURIDINE AND RADIATION THERAPY INVOLVING THE LIVER

溴脱氧尿苷和涉及肝脏的放射治疗

• 批准号: 5217604
• 负责人: JOHN M ROBERTSON
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5217604
• 关键词: bromodeoxyuridine; clinical research; clinical trial phase I; combination cancer therapy; human subject; human therapy evaluation; liver neoplasms; neoplasm /cancer radiation therapy

This is a Phase I protocol for patients with cancer involving the liver and porta hepatis using escalating dose rates of BUdR, a thymidine analog radiosensitizer, combined with hyperfractionated external beam irradiation. Radiation dose is determined through the use of three dimensional treatment planning techniques and is based on the volume of normal liver spared, in a manner identical to a previous version of 719 (however, the radiation doses have been decreased in this current protocol).

这是涉及肝脏的癌症患者的第一阶段治疗方案。 和肝门，使用递增的BUDR剂量率，一种胸苷类似物 放射增敏剂与超分割外照射相结合 辐射。辐射剂量是通过使用三个 立体治疗计划的技术和基础是体积 正常肝脏幸免于难，其方式与先前版本的719相同 (然而，在目前的情况下，辐射剂量已经减少 协议)。